Our studies provide further support for the direction of therapeutic modulation of TREM2, because an AD-protective PLCG2 variant has been shown to be mildly hypermorphic, indicating that increased PLCγ2 activity is beneficial for disease23,25. The gene discussed is PLCG2; the disease is Alzheimer disease.